(Approval lapsed) Hydromorphone hydrochloride 32mg extended-release tablets (Camber)
Section 19A approved medicine
(Approval lapsed) Hydromorphone hydrochloride 32mg extended-release tablets (Camber)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN ABN 92 124 728 894
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
JURNISTA hydromorphone hydrochloride 32 mg prolonged release tablet blister pack - ARTG 141534
Indication(s)
Hydromorphone hydrochloride extended-release tablet is indicated for the management of severe pain where:
- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. Hydromorphone hydrochloride extended-release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. Hydromorphone hydrochloride extended-release tablet is not indicated as an as-needed (PRN) analgesia. Not for use in opioid naive patients.
Images
